Cullinan Q2 net loss $42M; cash $664.9M; advancing CLN-978 IND in SLE for Q3 2024

Cullinan Therapeutics, Inc.

2024-Q2 EPS reported -$1.61

Net loss $42.0M vs $32.2M Q2 2023; R&D $36.3M, G&A $13.8M; cash runway into 2028.
CLN-978 (CD19xCD3 T cell engager) IND for SLE on track for Q3 2024; pursuing RA with FAU Erlangen & Università Cattolica.
CLN-619 combo data at ASCO showed objective responses in oncogenic mutation NSCLC; expansion cohorts added.
Positive initial zipalertinib data from REZILIENT1 study; ESMO presentation planned.
Discontinued CLN-418; returned rights to Harbour BioMed. Oversubscribed PIPE raised $280M in April.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.